Phillip Mullin Discharged After State's First Pediatric Lyfgenia Dose

Phillip Mullin has spent more than 100 nights in hospitals during his 15 years of life. On Friday, he left Manning Family Children's Hospital in New Orleans after becoming the first child in Louisiana to be functionally cured of sickle cell disease through gene therapy. He is also the first person in the state to receive Lyfgenia, a stem cell treatment that allows the body to produce normal red blood cells.

The Centers for Disease Control and Prevention notes that sickle cell disease causes abnormal red blood cells, leading to pain, infection, and stroke. For Mullin, the condition required frequent medical interventions and long periods of recovery. His treatment was formally recognized during a ceremony held Friday morning at the hospital, marking the end of his long course of care.

Mullin’s mother, Shataka Figgins, said the moment represents a shift from constant worry to relief. "I think I'll be unpacking every fear, every negative emotion that I had, every time I thought my baby wasn't going to be here with me," she said. She recalled sleepless nights and moments of doubt about her son’s ability to endure the pain, but now focuses on the young man who survived the process.

Mullin addressed the audience at the ceremony, noting that sacrifices are necessary to gain new strength. "You can't gain anything without first giving something in return, although if you can endure that pain and walk away from it, you find that you now have a heart strong enough to overcome any obstacle," he said. His remarks moved many in the room to tears.

He dedicated the milestone to his sister, Paige, whom he described as his superhero. Despite their playful banter, he stated that she is always there for him. Paige said she never imagined he would have this opportunity and described the moment as feeling great. Archie Manning, a New Orleans Saints legend and namesake of the hospital, attended the event and called the outcome a miracle, praising Mullin as a wonderful young man with a remarkable mind.

Mullin plans to return to school and eventually study to become a hematologist and oncologist. He wants to be a doctor who can relate to sickle cell patients because he knows what they are going through. For now, his immediate goal is to sleep in his own bed and build Legos with his baby sister.

The successful outcome marks a new chapter for pediatric sickle cell care in the region. Mullin’s case demonstrates the application of Lyfgenia in a young patient, providing a model for future treatments of the disease in Louisiana.